JUVISÉ-PHARMACEUTICALS
20.12.2019 08:02:09 CET | Business Wire | Press release
The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce the successful completion of a transaction with AstraZeneca, regarding the acquisition of the commercial rights of Arimidex® (anastrozole ) and Casodex® (bicalutamide ) in a number of European, African and other countries.
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceutical companies over the past years.
With this acquisition, Juvisé Pharmaceuticals enters the oncology therapeutic area, in which the company wants to further expand and consolidates its fast-growing ambition.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared “we are very pleased to have successfully closed our first deal with AstraZeneca and to enter a therapeutic area with high medical needs such as oncology with Arimidex® and Casodex®, which are two widely recognized cancer treatments essential for both patients and physicians”.
About Arimidex®
Arimidex® (anastrozole
) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy.
About Casodex®
Casodex® (bicalutamide
) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
About Juvisé Pharmaceuticals
Juvisé Pharmaceuticals is an international pharmaceutical company, specialized in manufacturing and commercializing ethical original drugs with high medical value for patients suffering from cardiovascular, oncology or neuro-psychiatric diseases.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own drugs in 75 countries around the word.
For more information, please visit juvisepharmaceuticals.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005652/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester Introduces AI Disruption Model To Assess AI’s Impact On Technology And Service Markets19.8.2026 11:00:00 CEST | Press release
With AI widening the divide across tech products and services, the model helps leaders identify the markets most likely to accelerate, transform, or face disruption According to Forrester’s (Nasdaq: FORR) AI Disruption Model, unveiled today, advancements in AI are disrupting technology markets at an unprecedented pace — enhancing the value of certain products and services while making others increasingly vulnerable to replacement. Two new reports, The Forrester AI Disruption Model: How AI Disrupts Or Accelerates Technology And Service Markets and The Forrester AI Disruption Model: Category Analysis, reveal that technology products and services that enable, secure, and govern AI are poised for significant growth due to organizations moving from experimentation to enterprise-scale deployment of AI applications and autonomous agents. In comparison, skills-based services will face disruption as AI assumes tasks that have traditionally depended on human expertise. Applied to 17 technology a
OKX Card Usage Surges Across Europe as Crypto Moves Into Everyday Spending19.8.2026 09:30:00 CEST | Press release
OKX Card purchase volume rises 280% year over year as European customers increasingly use digital assets for groceries, transport and other everyday expenses OKX, a leading global fintech company and crypto trading platform, today announced significant growth in everyday use of the OKX Card across Europe, with purchase volume increasing 280% year over year this summer and transactions rising 178%, as customers increasingly use the Card for routine spending including groceries, transport and fuel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819423550/en/ The OKX Card is designed to bridge the gap between holding digital assets and using them in everyday life, bringing earning, spending, and rewards together within the broader OKX ecosystem. The growth comes as crypto cards gain momentum across the wider payments industry. Industry-wide crypto card purchase volume reached a record $759 million in July, signalling that di
SAP strengthens its cloud infrastructure in Germany with BSI-approved Layer 1 encryption from Adva Network Security19.8.2026 09:00:00 CEST | Press release
News summary: SAP needed to secure connectivity between its German data centers to meet strict confidentiality, compliance and data control requirements BSI-approved Layer 1 encryption from Adva Network Security enables SAP to protect all data streams and future-proof its infrastructure against quantum threats Solution strengthens sovereign cloud foundations for government, critical infrastructure and regulated industries with high security and compliance needs Adva Network Security, an Adtran company, today announced that SAP is harnessing its Layer 1 encryption technology to secure connectivity between its data centers in Walldorf and St. Leon-Rot, Germany. The solution secures data directly at the optical transmission layer and is approved by the Federal Office for Information Security (BSI) for information classified up to “Verschlusssache – Nur für den Dienstgebrauch” (VS-NfD) – “For Official Use Only.” By strengthening the protection of data in transit, SAP is enhancing the secur
Qatar to Showcase Its Gaming Ambitions at Gamescom 202619.8.2026 09:00:00 CEST | Press release
Invest Qatar, the country’s Investment Promotion Agency, and Media City Qatar will participate at Gamescom 2026 through the “Qatar Pavilion”, highlighting Qatar’s growing role as a regional hub for game development, digital content and esports. Held annually in Cologne, Germany, Gamescom, a leading global event, brings together developers, publishers, investors and creators. Qatar’s participation reflects its focus on building a competitive, innovation-led ecosystem for gaming and interactive media. Mohammed Al Mulla, Head of Investment Development, Invest Qatar, said: “Gamescom provides a key platform to connect with global gaming leaders and highlight emerging opportunities across Qatar and the wider Middle East. We are focused on enabling companies to enter and scale in a high-growth market through a business environment designed for innovation and long-term success.” Dr. Fahad Abdulla Al Hajri, Business Development Manager, Media City Qatar, said: "Gaming is becoming one of the def
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom